Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial

BACKGROUND: Protection from lethal ventricular arrhythmias leading to sudden cardiac death (SCD) is a crucial challenge after acute myocardial infarction (AMI). Cardiac sympathetic and parasympathetic activity can be noninvasively assessed using heart rate variability (HRV) and heart rate turbulence...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Wataru, Kubota, Yoshiaki, Hoshika, Yu, Mozawa, Kosuke, Tara, Shuhei, Tokita, Yukichi, Yodogawa, Kenji, Iwasaki, Yu-ki, Yamamoto, Takeshi, Takano, Hitoshi, Tsukada, Yayoi, Asai, Kuniya, Miyamoto, Masaaki, Miyauchi, Yasushi, Kodani, Eitaro, Ishikawa, Masahiro, Maruyama, Mitsunori, Ogano, Michio, Tanabe, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519555/
https://www.ncbi.nlm.nih.gov/pubmed/32977831
http://dx.doi.org/10.1186/s12933-020-01127-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519555/
https://www.ncbi.nlm.nih.gov/pubmed/32977831
http://dx.doi.org/10.1186/s12933-020-01127-z

Ejemplares similares